Ask AI
ProCE Banner Activity

VISION: HRQoL, Pain, and Safety Outcomes With 177Lu-PSMA-617 in Previously Treated Metastatic Castration-Resistant Prostate Cancer

Slideset Download
Conference Coverage

In patients with previously treated mCRPC, the addition of 177Lu-PSMA-617 to standard of care resulted in improvements in health-related quality of life and time to worsening of pain and first symptomatic skeletal events, in addition to the previously reported OS and rPFS benefits.

Released: September 30, 2021

Expiration: September 29, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Daiichi Sankyo, Inc.

Exelixis, Inc.

Ipsen Biopharmaceuticals Inc